Anebulo Pharmaceuticals Stock Today

ANEB Stock  USD 2.47  0.20  8.81%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 20

 
High
 
Low
Low
Anebulo Pharmaceuticals is trading at 2.47 as of the 13th of July 2024, a 8.81 percent increase since the beginning of the trading day. The stock's open price was 2.27. Anebulo Pharmaceuticals has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Anebulo Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of June 2024 and ending today, the 13th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of May 2021
Category
Healthcare
Classification
Health Care
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. The company was incorporated in 2020 and is based in Lakeway, Texas. The company has 25.93 M outstanding shares of which 12.53 K shares are presently shorted by private and institutional investors with about 2.8 trading days to cover. More on Anebulo Pharmaceuticals

Moving together with Anebulo Stock

  0.64VRDN Viridian Therapeutics Buyout TrendPairCorr

Moving against Anebulo Stock

  0.62PFE Pfizer Inc Aggressive PushPairCorr
  0.61VRAX Virax Biolabs GroupPairCorr
  0.54ESPR Esperion TherapeuticsPairCorr
  0.37VALN Valneva SE ADRPairCorr
  0.32XWEL XWELL IncPairCorr

Anebulo Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO DirectorRichard Cunningham
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities416 K614.7 K
Way Down
Slightly volatile
Non Current Liabilities Total804.5 K480.8 K
Way Up
Slightly volatile
Total Assets14.3 M13.4 M
Notably Up
Slightly volatile
Total Current Assets13.4 M12.9 M
Sufficiently Up
Slightly volatile
Debt Levels
Anebulo Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Anebulo Pharmaceuticals' financial leverage. It provides some insight into what part of Anebulo Pharmaceuticals' total assets is financed by creditors.
Liquidity
Anebulo Pharmaceuticals currently holds 1.07 M in liabilities. Anebulo Pharmaceuticals has a current ratio of 29.79, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Anebulo Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Change In Cash

(2.82 Million)
Anebulo Pharmaceuticals (ANEB) is traded on NASDAQ Exchange in USA. It is located in 1017 Ranch Road 620 South, Lakeway, TX, United States, 78734 and employs 2 people. Anebulo Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 58.87 M. Anebulo Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 25.93 M outstanding shares of which 12.53 K shares are presently shorted by private and institutional investors with about 2.8 trading days to cover. Anebulo Pharmaceuticals currently holds about 14.55 M in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62.
Check Anebulo Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Anebulo Pharmaceuticals shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.37 percent of Anebulo Pharmaceuticals outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event.
Check Anebulo Ownership Details

Anebulo Stock Institutional Holders

InstituionRecorded OnShares
Ubs Group Ag2024-03-31
144
Wells Fargo & Co2024-03-31
62.0
Royal Bank Of Canada2024-03-31
38.0
Jpmorgan Chase & Co2024-03-31
9.0
Adar1 Capital Management Llc2024-03-31
0.0
Landscape Capital Management,llc2024-03-31
0.0
Praetorian Pr Llc2023-12-31
0.0
Mangrove Partners2023-12-31
0.0
Bank Of America Corp2024-03-31
0.0
22nw, Lp2024-03-31
5.4 M
Lvw Advisors, Llc2024-03-31
642 K
View Anebulo Pharmaceuticals Diagnostics

Anebulo Pharmaceuticals Historical Income Statement

At present, Anebulo Pharmaceuticals' Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 7.5 M, whereas Depreciation And Amortization is forecasted to decline to about 10.1 K. View More Fundamentals

Anebulo Stock Against Markets

Anebulo Pharmaceuticals Corporate Management

Already Invested in Anebulo Pharmaceuticals?

The danger of trading Anebulo Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Anebulo Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Anebulo Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Anebulo Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Information and Resources on Investing in Anebulo Stock

When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anebulo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Return On Assets
(0.58)
Return On Equity
(1.04)
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.